380 related articles for article (PubMed ID: 30285841)
21. Examination of the Level of Circulating Plasmablasts and Their Characteristics as Diagnostic Tools for Immunoglobulin G4-related Disease.
Tartakover Matalon S; Rabinowicz N; Carmi O; Zitman-Gal T; Drucker L; Levy Y
Isr Med Assoc J; 2024 Jun; 26(6):369-375. PubMed ID: 38884310
[TBL] [Abstract][Full Text] [Related]
22. B-Cell depletion therapy in IgG4-related disease: State of the art and future perspectives.
Lanzillotta M; Stone JH; Della-Torre E
Mod Rheumatol; 2023 Mar; 33(2):258-265. PubMed ID: 35983918
[TBL] [Abstract][Full Text] [Related]
23. Serum IgG4 levels at diagnosis can predict unfavorable outcomes of untreated patients with IgG4-related disease.
Mizushima I; Konishi M; Sanada H; Suzuki K; Takeji A; Zoshima T; Hara S; Ito K; Fujii H; Yamada K; Kawano M
Sci Rep; 2021 Jun; 11(1):13341. PubMed ID: 34172819
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Liu Y; Zhang Y; Bian W; Fu J; Sun X; Chen D; Chen J; Zhao X; Li Y; Zhang W; Li Z
Clin Rheumatol; 2020 Feb; 39(2):491-497. PubMed ID: 31848912
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease.
Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L
Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297
[TBL] [Abstract][Full Text] [Related]
26. HLA-DRB1 Is Associated with Therapeutic Responsiveness in IgG4-related Disease.
Yamamoto M; Tanaka T; Aochi S; Uehara M
Intern Med; 2024 Jan; 63(2):207-211. PubMed ID: 37225483
[TBL] [Abstract][Full Text] [Related]
27. Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage.
Zhang P; Zhang Y; Pan M; Liu Z; Li J; Peng L; Zhou J; Hu C; Liu S; Zeng X; Ge W; Zhang W
J Autoimmun; 2021 Aug; 122():102650. PubMed ID: 34107438
[TBL] [Abstract][Full Text] [Related]
28. Predictors of disease relapse in IgG4-related disease following rituximab.
Wallace ZS; Mattoo H; Mahajan VS; Kulikova M; Lu L; Deshpande V; Choi HK; Pillai S; Stone JH
Rheumatology (Oxford); 2016 Jun; 55(6):1000-8. PubMed ID: 26888853
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
30. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease.
Akiyama M; Yasuoka H; Yamaoka K; Suzuki K; Kaneko Y; Kondo H; Kassai Y; Koga K; Miyazaki T; Morita R; Yoshimura A; Takeuchi T
Arthritis Res Ther; 2016 Jul; 18():167. PubMed ID: 27411315
[TBL] [Abstract][Full Text] [Related]
31. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients.
Wang L; Zhang P; Zhang X; Lin W; Tang H; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Zhang L; Lai Y; Zeng X; Li X; Xue H; Zhao Y; Zhang F; Zhang W
Rheumatology (Oxford); 2019 May; 58(5):820-830. PubMed ID: 30561747
[TBL] [Abstract][Full Text] [Related]
32. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
33. Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease.
Li J; Liu Z; Zhang P; Lin W; Lu H; Peng Y; Peng L; Zhou J; Wang M; Chen H; Zhao L; Wang L; Qin C; Hu C; Zeng X; Zhao Y; Fei Y; Zhang W
Front Immunol; 2021; 12():747076. PubMed ID: 34603334
[TBL] [Abstract][Full Text] [Related]
34. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
36. B lymphocytes directly contribute to tissue fibrosis in patients with IgG
Della-Torre E; Rigamonti E; Perugino C; Baghai-Sain S; Sun N; Kaneko N; Maehara T; Rovati L; Ponzoni M; Milani R; Lanzillotta M; Mahajan V; Mattoo H; Molineris I; Deshpande V; Stone JH; Falconi M; Manfredi AA; Pillai S
J Allergy Clin Immunol; 2020 Mar; 145(3):968-981.e14. PubMed ID: 31319101
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.
Perugino CA; Wallace ZS; Zack DJ; Quinn SM; Poma A; Fernandes AD; Foster P; DeMattos S; Burington B; Liu H; Allard-Chamard H; Smith N; Kai X; Xing K; Pillai S; Stone JH
Lancet Rheumatol; 2023 Aug; 5(8):e442-e450. PubMed ID: 38251576
[TBL] [Abstract][Full Text] [Related]
38. Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.
Zhao Z; Liu Y; Bai M; Zeng Q; Wang Z; Chen D; Li Z; Su Y
Clin Exp Rheumatol; 2023 Sep; 41(9):1808-1814. PubMed ID: 36826798
[TBL] [Abstract][Full Text] [Related]
39. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
40. Development of targeted therapies in IgG4-related disease.
Nakayamada S; Tanaka Y
Mod Rheumatol; 2023 Mar; 33(2):266-270. PubMed ID: 35983919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
